Pharmacy and Poisons Board lifts ban on popular painkiller Mefnac Oral Suspension

Pharmacy and Poisons Board lifts ban on popular painkiller Mefnac Oral Suspension

The restriction, which was initially imposed on December 11, 2024, was placed as a precautionary measure to allow for thorough investigations into the safety and quality of the drug.

The Pharmacy and Poisons Board has lifted the quarantine order on Mefnac Oral Suspension (Mefenamic Acid 50mg/5ml), a widely used painkiller manufactured by Efroze Chemical Industries Pvt Ltd, Pakistan.

The restriction, which was initially imposed on December 11, 2024, was placed as a precautionary measure to allow for thorough investigations into the safety and quality of the drug.

In a statement, Chief Executive Officer FM Suyoi confirmed that laboratory analysis and investigations had determined the product met all safety and quality standards.

"The investigation results on the product meet all applicable specifications, and it is safe for distribution and use," he stated.

The lifting of the quarantine means that Mefnac Oral Suspension can now be legally distributed, sold, and prescribed within the country to patients in need of pain relief.

“The Board encourages the public to report any concerns about substandard medicines or adverse reactions to healthcare facilities or the pharmacy and poisonous boards.

Mefnac Oral Suspension (Mefenamic Acid 50mg/5ml) is a widely used pain reliever that belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs).

It is primarily prescribed for children, particularly to manage pain, fever, and inflammation associated with teething, flu, mild infections, and post-vaccination fever.

Women frequently use Mefenamic Acid to relieve menstrual cramps, while adults and elderly patients rely on it for arthritis, joint pain, muscle injuries, and dental discomfort after procedures. Additionally, it is sometimes prescribed for mild to moderate post-surgical pain.

Reader Comments

Stay ahead of the news! Click ‘Yes, Thanks’ to receive breaking stories and exclusive updates directly to your device. Be the first to know what’s happening.